{"id":"W2070028004","doi":"10.1016/j.jval.2014.03.485","title":"Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Trametinib; Dacarbazine; Vemurafenib; Medicine; Internal medicine; Oncology; Melanoma; Metastatic melanoma; Chemotherapy; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002511559,0.0007910132,0.001005413,0.002293092,0.001496697,0.004722577,0.001515387,0.00250541,0.007076392],"category_scores_gemma":[0.01144781,0.0003050507,0.002095911,0.003933763,0.001122429,0.001144388,0.0009381335,0.00288993,0.0002753251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08935536,"about_ca_system_score_gemma":0.09236475,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9508193,"about_ca_topic_score_gemma":0.9606139,"domain_scores_codex":[0.9969102,0.0007930323,0.000126185,0.0001613754,0.001226328,0.000782958],"domain_scores_gemma":[0.9929361,0.001231614,0.0007894734,0.0000625152,0.003168181,0.001812048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.008820375,0.0008782276,0.1428363,0.003764087,0.005655734,0.001578233,0.001038158,0.0714494,0.002611167,0.1046752,0.239463,0.4172302],"study_design_scores_gemma":[0.002725472,0.002538394,0.5754866,0.008577676,0.01060498,0.00241308,0.006532389,0.07169677,0.001485984,0.03573343,0.2811919,0.001013419],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.2484607,0.1708073,0.00218082,0.40649,0.00269244,0.0002591748,0.02911102,0.0001484529,0.1398502],"genre_scores_gemma":[0.9309218,0.04706194,0.001665816,0.01043678,0.001190732,0.00004699826,0.003821043,0.0000383937,0.004816424],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.08935536,"threshold_uncertainty_score":0.6483215,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0471651896086674,"score_gpt":0.3426153436142328,"score_spread":0.2954501540055655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}